Biotech Values

[DonShimoda]

Thanks for the exchange...being able to test ones's assumptions is one the great things about this board.

btw, just to thoroughly confuse the matter, Ariad recently made the case that T315I was not a predictor for response. Surprisingly, the high response rate in T315I isn't specific to the mutation but is more a function of getting on the drug sooner(perhaps due to earlier testing). If that's indeed the case, it could have an interesting implication for the front-line EPIC trial which by definition enrolls patients who have a shorter time since diagnosis.